Single centre, open-label, multiple doses, two parallel study groups each receiving two formulations in a one-sequence design:~Group A: Pre-treatment with ESL, treatment with ESL and ascending doses of phenytoin (PHT) in last phases;~Group B: Pre-treatment with PHT, treatment with PHT and ascending doses of ESL in last phases
Single centre, open-label, multiple doses, two parallel study groups each receiving two formulations in a one-sequence design